Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated
Tip Ranks·- Maxim Group analyst Jason McCarthy maintained a buy rating on Cellectar Biosciences with a target price of 10.00 dollars. - The rating is supported by a robust financial position ensuring operations through the second quarter of 2027 and risk-reducing clinical milestones. - Additional backing comes from potential pipeline expansion in triple-negative breast cancer and favorable trial efficacy data.Cellectar Biosciences Q2 2026 Earnings Call Transcript
benzinga_article·